Haemocoagulase - Lee's Pharmaceutical

Drug Profile

Haemocoagulase - Lee's Pharmaceutical

Alternative Names: Slounase

Latest Information Update: 31 May 2012

Price : $50

At a glance

  • Originator Lees Pharmaceutical Holdings
  • Class Coagulants; Crotalid venoms; Serine endopeptidases
  • Mechanism of Action Fibrinogen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Blood coagulation disorders

Most Recent Events

  • 14 Oct 2005 Launched for Coagulation disorders in China (Parenteral)
  • 14 Oct 2005 Registered for Coagulation disorders in China (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top